SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001867096-23-000097
Filing Date
2023-06-07
Accepted
2023-06-07 16:58:04
Documents
1
Period of Report
2023-06-07

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1686171475.html 4  
1 FORM 4 wk-form4_1686171475.xml 4 3480
  Complete submission text file 0001867096-23-000097.txt   4862
Mailing Address C/O XERIS PHARMACEUTICALS 180 N. LASALLE ST., STE. 1800 CHICAGO IL 60601
Business Address
HALKUFF DAWN (Reporting) CIK: 0001743658 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40880 | Film No.: 23999679

Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations